NL-OMON33667已完成不适用
A(f)MAZE-CABG study;A PROSPECTIVE RANDOMIZED TRIAL COMPARING FREEDOM FROM ATRIAL FIBRILLATION AT 1 YEAR POST CABG IN PATIENTS UNDERGOING CONCOMITANT LEFT ATRIAL ABLATION USING HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) VERSUS CABG ALONE IN PATIENTS WITH PERSISITENT OR LONG STANDING PERSISTENT ATRIAL FIBRILLATION ;Study Code: AF07004AF - A(f) MAZE-CABG study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Legal age in host country
- •Scheduled for CABG surgery
- •Patient suffering from persistent or long-standing persistent AF
- •Patients having the ability to fully comply with the study requirements
- •Life expectancy > 2 years
- •Patients who have given written informed consent to participate in the study
排除标准
- •Clinically significant local or systemic infection or active endocarditis
- •Sutures, pacing/defibrillator leads on the left side of the heart, valve prostheses or rings, or other implanted material in or adjacent to target treatment area.
- •Stent in the coronary artery preventing an adequate mitral line
- •Any other concomitant operation on the heart
- •Previous heart surgery
- •Patients who are or may potentially be pregnant
- •Previous catheter ablation for atrial arrhythmia
- •LA size more than 60 mm in apical view on Trans-Thoracic Echocardiogram (TTE)
- •LA thrombus on intra-operative Trans-Oesophageal Echocardiogram (TOE)
- •Known contraindication to Amiodarone
- •Inability to undergo TOE
- •Patients who are unable to give full informed consent for the study.
研究者
相似试验
尚未招募
3 期
A randomized competitive trial of BCG instillation therapy with UFT for prevention of superficial bladder cancer recurrence.Bladder cancerJPRN-UMIN000001861Study Group of Urothelial Cancer Kitasato institute hospital Kitasato University Kyorin University Keio University Showa University Teikyo University Tokyo Medical University Jikei University Toho University354
尚未招募
2 期
Evaluation of BCG as potential therapy for COVID-19CTRI/2020/05/025013Medical Education and Drugs Department
进行中（未招募）
1 期
A Phase 3, Randomized, Double-Blind Study of BGB A1217, an Anti TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD L1 Selected, and Locally Advanced, Unresectable, or Metastatic Non Small Cell Lung CancerPreviously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable,or Metastatic Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004985-21-FRBeiGene, Ltd.605
进行中（未招募）
1 期
A Phase 3, Randomized, Double-Blind Study of BGB A1217, an Anti TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD L1 Selected, and Locally Advanced, Unresectable, or Metastatic Non Small Cell Lung CancerPreviously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004985-21-ITBeiGene Ltd.605
招募中
不适用
To test the disease free survival (DFS) prediction ability of the OncoDiscover diagnostic technology â?? a simple liquid biopsy blood test for cancer patients.CTRI/2018/04/012920Actorius Innovations and Research Pvt Ltd